​

Aardvark Therapeutics Stock (NASDAQ:AARD)

ForecastOwnershipFinancialsChart
Aardvark Therapeutics by TradingView

Previous Close

$3.90

52W Range

$3.35 - $17.94

50D Avg

$7.97

200D Avg

$11.19

Market Cap

$85.96M

Avg Vol (3M)

$291.11K

Beta

5.34

Div Yield

-

AARD Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

22

IPO Date

Feb 13, 2025

Website

AARD Performance

AARD Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-62.73M$-22.79M$-7.42M
Net Income$-57.59M$-20.59M$-7.21M
EBITDA$-62.73M$-22.65M$-6.65M
Basic EPS$-2.93$-1.59$-0.56
Diluted EPS$-2.93$-1.59$-0.56

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
FHTXFoghorn Therapeutics Inc.
PYXSPyxis Oncology, Inc.
ENTAEnanta Pharmaceuticals, Inc.
TNYATenaya Therapeutics, Inc.
AVTXAvalo Therapeutics, Inc.
ASMBAssembly Biosciences, Inc.
EPRXEupraxia Pharmaceuticals Inc.
NAUTNautilus Biotechnology, Inc.
CRBUCaribou Biosciences, Inc.
ZURAZura Bio Limited